![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Stanford University Department of Defense |
---|---|
Information provided by: | Stanford University |
ClinicalTrials.gov Identifier: | NCT00186108 |
The primary purpose of this study is to evaluate the ability of oral triamcinalone given twice a day to patients with androgen independent prostate cancer to produce a sustained biochemical response. Secondary goals are to describe the safety and tolerability at this dose and schedule, to determine the time to sustained biochemical response, to determine the duration of biochemical response, to determine the time to disease progression.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: Oral Triamcinalone |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment |
Official Title: | A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer |
Enrollment: | 23 |
Study Start Date: | October 2002 |
Study Completion Date: | September 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion criteria:
United States, California | |
Stanford University Cancer Center | |
Stanford, California, United States, 94305 |
Principal Investigator: | Sandy Srinivas, MD | Stanford University |
Study ID Numbers: | PROS0006 |
Study First Received: | September 13, 2005 |
Last Updated: | July 24, 2007 |
ClinicalTrials.gov Identifier: | NCT00186108 |
Health Authority: | United States: Institutional Review Board |
Oral Triamcinalone Prostate Cancer |
Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Neoplasms Neoplasms by Site |